Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

https://investor.lilly.com/news-releases/news-release-details/lilly-and-junshi-biosciences-co-develop-antibody-therapies

https://www.prnewswire.com/news-releases/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of-covid-19-301051788.html

https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0504/2020050400017.pdf

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 (a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock code: 1877) INSIDE INFORMATION－ ENTERING INTO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH LILLY

http://www.caixin.com/2020-05-05/101550272.html

Eli Lilly teams up with Chinese company Junshi to develop Covid-19 therapy

https://www.caixinglobal.com/2020-05-05/china-business-digest-global-infections-top-358-million-kingsoft-cloud-super-sizes-fundraising-target-for-us-ipo-101550249.html

THERAPEUTIC AREAS

BiotechVortex™

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

Thu April 2, 2020 8:00 AM|Business Wire|About: HZNP

-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment --

-- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)

https://www.horizontherapeutics.com/

https://www.horizontherapeutics.com/our-pipeline/

https://www.businesswire.com/news/home/20200402005203/en/

https://seekingalpha.com/symbol/HZNP

Horizon snaps up Curzion Pharma and its ex-Sanofi rare disease drug by Ben Adams | Apr 3, 2020 8:25am

Becton Dickinson, BioGX Get FDA Emergency Use Authorization For Rapid SARS-CoV-2 Test

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S.

Fri April 3, 2020 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX), a leading global medical technology company, and BioGX Inc.

https://www.bd.com/en-us

http://biogx.com/

https://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html

https://seekingalpha.com/symbol/BDX

http://biogx.com/news/becton-dickinson-biogx-get-fda-emergency-use-authorization-for-rapid-sars-cov-2-test

https://biogx.com/

PRODUCTS

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Mon April 6, 2020 8:01 AM|GlobeNewswire|About: GSK, VIR

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months
GSK to make equity investment of $250 million in Vir

LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. (VIR)

https://www.vir.bio/science/#programs

https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus

https://seekingalpha.com/symbol/GSK

Technology platforms Our four current technologies are designed to stimulate and enhance the immune system.

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Mon April 6, 2020 6:15 AM|Business Wire|About: GILD

-- Multi-year, Multi-program Agreement Leverages Latest Insights of Microbiome --

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Second Genome

https://www.businesswire.com/news/home/20200406005220/en/

https://www.secondgenome.com/

https://seekingalpha.com/symbol/GILD

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery

Second Genome has developed a rich pipeline of drug candidates through our differentiated approach.

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

Mon April 6, 2020 7:00 AM|Business Wire|About: ALNY, DRNA

- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization -

- Companies Complete Non-Exclusive Intellectual Property Cross-License Agreement for the Development and Commercialization of Alnylam’s Lumasiran and Dicerna’s Nedosiran Investigational Programs for Primary Hyperoxaluria -

CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (DRNA) (Nasdaq: DRNA)

https://www.alnylam.com/

https://www.alnylam.com/alnylam-rnai-pipeline/

https://seekingalpha.com/symbol/ALNY

https://dicerna.com/

https://dicerna.com/pipeline/

https://seekingalpha.com/symbol/DRNA

https://www.businesswire.com/news/home/20200406005200/en/

Alpha-1 antitrypsin deficiency

https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency#

Primary hyperoxaluria

https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria

RNAi therapies to target the cause of disease

Regeneron & Zai Lab Announce Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Wed April 8, 2020 6:00 AM|GlobeNewswire|About: REGN, ZLAB

Zai Lab (ZLAB) obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau

Collaboration will also support enrollment of regional patients into Regeneron’s global trials evaluating REGN1979 in B-cell non-Hodgkin lymphoma (B-NHL)

Zai Lab to host conference call and webcast today at 8:00 a.m. EST

TARRYTOWN, N.Y. and SHANGHAI, China, April 08, 2020 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Zai Lab Limited

https://www.regeneron.com/

http://www.zailaboratory.com/

https://www.regeneron.com/pipeline

http://www.zailaboratory.com/pipeline/list.aspx

https://seekingalpha.com/symbol/ZLAB

https://seekingalpha.com/symbol/REGN

INTERACT WITH THE REGENERON PIPELINE Pipeline last updated: February 13, 2020

BiotechVortex™

Generation Bio & Vir Biotechnology Collaborate on Scalable Non-Viral Gene Therapy Platform

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

Mon March 30, 2020 7:00 AM|Business Wire|About: VIRQ4: 03-26-20 Earnings SummaryEPS of $-0.69 misses by $-0.06 Revenue of $0.98M (-% Y/Y) misses by $-1.59M

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Generation Bio and Vir Biotechnology (VIR) (Nasdaq: VIR)

https://www.businesswire.com/news/home/20200330005148/en/

https://generationbio.com/

https://www.vir.bio/pipeline/

We are committed to enabling generations of people with genetic diseases to live long, full lives.

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

Tue March 31, 2020 6:30 AM|PR Newswire|About: LLY

INDIANAPOLIS and OXFORD, England, March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an exclusive global licensing and research collaboration with Sitryx,

https://www.prnewswire.com/news-releases/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines-301032137.html

http://www.sitryx.com/

http://www.sitryx.com/news-and-events/press-releases/2020/

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation.

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Tue March 31, 2020 7:30 AM|Newsfile|About: NNVCNewsfile Corp

The Company's Update on its Development of COVID-19 Drug Candidate is Promising

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NNVC) (

http://www.nanoviricides.com/

http://www.nanoviricides.com/pipeline.html

https://smallcapsdaily.com/nanoviricides-the-latest-covid-19-drug-update-looks-promising/

https://seekingalpha.com/symbol/NNVC

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

Tue March 31, 2020 2:00 PM|GlobeNewswire|About: SRNE

SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.

https://sorrentotherapeutics.com/

https://som.utmb.edu/

Immuno-Oncology

https://sorrentotherapeutics.com/pipeline/

https://seekingalpha.com/symbol/SRNE

COVID-19: UPDATE FROM THE SCHOOL OF MEDICINE

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Tue March 31, 2020 4:05 PM|PR Newswire|About: RARE, RGNX

- Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO

PR Newswire

ROCKVILLE, Md. and NOVATO, Calif., March 31, 2020 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE),

https://www.ultragenyx.com/

https://www.regenxbio.com/

https://www.ultragenyx.com/pipeline/

https://www.regenxbio.com/therapeutic-programs/

https://seekingalpha.com/symbol/RGNX

https://seekingalpha.com/symbol/RARE

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

Tue March 31, 2020 4:05 PM|GlobeNewswire|About: EBS, NVAX

CDMO agreement for NanoFlu to support pathway to licensure
Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced an agreement with Novavax, Inc. (NVAX)

https://www.emergentbiosolutions.com/

https://novavax.com/

https://www.emergentbiosolutions.com/pipeline

https://novavax.com/page/8/vaccine-technology.html

https://seekingalpha.com/symbol/NVAX

https://seekingalpha.com/symbol/EBS

NanoFlu – Nanoparticle Seasonal Influenza Vaccine - Older Adults (65+ yrs)

https://novavax.com/page/11/clinical-stage-pipeline.html

Product Candidate & Device Candidate

BiotechVortex™

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Tue March 24, 2020 9:32 AM|GlobeNewswire|About: SRNE

ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cycle
ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm’s 30,000 m2 cGMP facilities in China for human clinical trials and commercialization upon receipt of requisite regulatory approvals
Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK,

https://sorrentotherapeutics.com/

http://www.mabpharm.cn/en/index.php

https://sorrentotherapeutics.com/pipeline/

https://seekingalpha.com/symbol/SRNE

https://apnews.com/Globe%20Newswire/5a08618b12f6f2f70ac2bc199b48324a

http://www.mabpharm.cn/en/research_product.php

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19 Sorrento Therapeutics, Inc. today

Multi-Lingual Support = Global MediXchange of Combating COVID-19 (GMCC)-Medical Personnel Worldwide

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

Multi-Lingual Support From the Global MediXchange of Combating COVID-19 (GMCC) Programme to Further Enable Sharing Among Medical Personnel Worldwide

Wed March 25, 2020 11:43 PM|Business Wire|About: BABA

HANGZHOU, China--(BUSINESS WIRE)

https://www.alibabacloud.com/solutions/dingtalk/international-medical-expert-communication-platform?spm=a3c0i.14157329.6596852130.2.1bf2772d5A46tB

Resources Sharing Center

Fight COVID-19 without having to start from scratch

https://covid-19.alibabacloud.com/#J_8102420620

The Chinese Telemedicine Team
Is Here to Fight against COVID-19

International Medical Expert Communication Center
Is Officially Launched

https://covid-19.alibabacloud.com/

https://www.businesswire.com/news/home/20200325005799/en/

https://seekingalpha.com/symbol/BABA

International Medical Expert Communication Center Alibaba's DingTalk provides a communication center for experts all over the world to communicate seamlessly with global doctors who can share their invaluable experience of fighting coronavirus disease 2019 (COVID-19).

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Thu March 26, 2020 7:30 AM|GlobeNewswire|About: DVAXGlobeNewswire

EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX) (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI)

https://www.dynavax.com/

https://cepi.net/

https://www.fda.gov/

http://investors.dynavax.com/node/17866/pdf

https://seekingalpha.com/symbol/DVAX

http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-cepi-announce-collaboration-support-global-effort

New vaccines for a safer world The Coalition for Epidemic Preparedness Innovations (CEPI) is a global alliance financing and coordinating the development of vaccines against emerging infectious diseases.

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Fri March 27, 2020 2:00 AM|GlobeNewswire|About: SNY, TBIO

The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development

PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), and Translate Bio (TBIO)

https://translate.bio/

https://seekingalpha.com/symbol/SNY

https://seekingalpha.com/symbol/TBIO

https://www.sanofi.com/

https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00

Translate Bio Provides MRT5005 Program Updates

Thu March 26, 2020 4:30 PM|GlobeNewswire|About: TBIO

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –

-- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial operations; updated interim data readout timing to be provided at later date --

LEXINGTON, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio (TBIO)

https://seekingalpha.com/pr/17820487-translate-bio-provides-mrt5005-program-updates

https://translate.bio/pipeline/

Our MRTTM platform is potentially applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease. Our MRTTM platform may also be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Mon March 30, 2020 7:22 AM|PR Newswire|About: JNJ

Johnson & Johnson (JNJ) and BARDA

https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies

Novel Coronavirus, SARS-CoV-2

https://www.jnj.com/coronavirus

https://www.jnj.com/

https://www.prnewswire.com/news-releases/johnson--johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health--human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use-301031582.html

https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses GloballyApr 23, 2020Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its InvestmentFirst in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19

NEW BRUNSWICK, N.J., April 23, 2020 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE: JNJ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, I

https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/johnson-johnson-announces-collaboration-expand-manufacturing

https://www.emergentbiosolutions.com/manufacturing-expertise

https://www.emergentbiosolutions.com/

Cutting-edge technologies are the driving force behind our strong research and development pipeline

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Medtronic Shares Ventilation Design Specifications to Accelerate Efforts to Increase Global Ventilator Production

Mon March 30, 2020 8:15 AM|GlobeNewswire|About: MDT

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) (NYSE:MDT)

https://www.fda.gov/media/136318/download

https://www.medtronic.com/us-en/index.html

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-shares-ventilation-design-specifications-accelerate

https://seekingalpha.com/symbol/MDT

Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency Guidance for Industry and Food and Drug Administration Staff March 2020

BiotechVortex™

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

Fri March 13, 2020 9:41 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., March 13, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC)

Cutting-edge technologies are the driving force behind our strong research and development pipeline

https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies

https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic

https://www.jnj.com/coronavirus

https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

Mon March 16, 2020 7:30 AM|PR Newswire|About: ACRX

Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction

Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative treatments to healthcare institutions

AcelRx and Tetraphase also enter into co-promotion agreement expected to generate significant commercial synergies immediately

Acquisition expected to close in Q2 2020

PR Newswire

REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX)

https://www.acelrx.com/

https://www.tphase.com/#

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals-301024578.html

https://www.tphase.com/products/xerava/

https://seekingalpha.com/symbol/ACRX

AcelRx to acquire Tetraphase in a stock for stock transaction Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative treatments to healthcare institutions AcelRx and Tetraphase also enter into co-promotion agreement expected to generate significant commercial synergies immediately Acquisition expected to close in Q2 2020 REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

IDE196, a Protein Kinase C (PKC) inhibitor, and binimetinib, a MEK inhibitor

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

Wed March 18, 2020 6:00 AM|PR Newswire|About: IDYA, PFEPR Newswire

SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (IDYA),

https://www.prnewswire.com/news-releases/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-binimetinib-in-solid-tumors-harboring-gnaq-or-gna11-hotspot-mutations-301025907.html

https://www.ideayabio.com/

https://seekingalpha.com/symbol/IDYA

https://seekingalpha.com/symbol/PFE

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

https://clinicaltrials.gov/ct2/show/NCT03947385?term=ideaya&draw=2&rank=1

Breakthrough Oncology Medicines

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

Thu March 19, 2020 6:50 PM|PR Newswire|About: DHR, GE

WASHINGTON, March 19, 2020 /PRNewswire/ -- Danaher Corporation (DHR)

https://www.danaher.com/

https://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html

https://seekingalpha.com/symbol/DHR

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Mon March 23, 2020 7:00 AM|GlobeNewswire|About: ACIU

CHF 10 million milestone recognizes development progress
Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation
Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

LAUSANNE, Switzerland, March 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU) (NASDAQ: ACIU)

https://www.acimmune.com/

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-and-lilly-announce-license-and-collaboration-agreement?field_nir_news_date_value%5bmin%5d=2019

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-initiates-phase-1-study-aci-3024-small-molecule-tau?field_nir_news_date_value%5bmin%5d=2019

https://seekingalpha.com/symbol/ACIU

AC Immune and Lilly Announce License and Collaboration Agreement December 12, 2018

Updates from Lilly about insulin supply and affordability

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Updates from Lilly about insulin supply and affordability

Tue March 24, 2020 8:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, March 24, 2020 /PRNewswire/

https://www.prnewswire.com/news-releases/updates-from-lilly-about-insulin-supply-and-affordability-301028654.html

IDF DIABETES ATLAS

9th edition 2019

https://diabetesatlas.org/en/

https://www.facebook.com/LillyDiabetesUS/

https://www.lillydiabetes.com/

Updates from Lilly about insulin supply and affordability 03/24/2020 Download PDF INDIANAPOLIS, March 24, 2020 /PRNewswire/

BiotechVortex™

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

Wed March 11, 2020 8:00 AM|GlobeNewswire|About: VIRGlobeNewswire

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology (VIR), Inc. (Nasdaq: VIR)

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses 03/11/20 at 8:00 AM EDT PDF Version Joint research project to include SARS-CoV-2 SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR)

Vir Biotechnology to Collaborate w Biogen on Manufacturing of Antibodies to Treat COVID-19

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

03/12/20 at 8:00 AM EDTPDF Version

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB)

Vir Biotech up 27% premarket on COVID-19 deal with Biogen

Mar. 12, 2020 8:40 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3551009-vir-biotech-up-27-premarket-on-covidminus-19-deal-biogen

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Thu March 12, 2020 7:00 AM|PR Newswire|About: STRO

SOUTH SAN FRANCISCO, Calif., March 12, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO)

https://www.sutrobio.com/

https://www.prnewswire.com/news-releases/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck-301022013.html

https://seekingalpha.com/symbol/STRO

https://seekingalpha.com/symbol/MRK

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck March 12, 2020 SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Merck,

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Thu March 12, 2020 7:00 AM|PR Newswire

CARLSBAD, Calif., March 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific

https://www.thermofisher.com/us/en/home.html

http://thermofisher.mediaroom.com/2020-03-12-Thermo-Fisher-Scientific-Signs-Agreement-with-Janssen-to-Co-Develop-Companion-Diagnostic-for-Cancer

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-signs-agreement-with-janssen-to-co-develop-companion-diagnostic-for-cancer-301022011.html

https://seekingalpha.com/symbol/TMO

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer CARLSBAD, Calif., March 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific announced today it has signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) in oncology. The CDx will support clinical trial enrollment globally.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Wed March 11, 2020 10:45 AM|GlobeNewswire|About: NVAX

Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University
Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX)

https://www.who.int/publications-detail/world-malaria-report-2019

https://www.novavax.com/

https://www.seruminstitute.com/

https://www.novavax.com/page/11/clinical-stage-pipeline.html

https://seekingalpha.com/symbol/NVAX

CLINICAL STAGE PIPELINE

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thu March 12, 2020 6:11 PM|PR Newswire|About: LLYPR Newswire

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (LLY)

https://www.abcellera.com/

https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

https://www.prnewswire.com/news-releases/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19-301022689.html

https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment

ABCELLERA AND LILLY TO CO-DEVELOP ANTIBODY THERAPIES FOR THE TREATMENT OF COVID-19

BiotechVortex™

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

CVS Kidney Care, Satellite Healthcare Enter Strategic Relationship to Advance the Care of Patients with Kidney Disease

Mon March 2, 2020 4:30 PM|PR Newswire|About: CVS

WOONSOCKET, R.I. and SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- CVS Kidney Care, a CVS Health (CVS) company, and Satellite Healthcare

https://www.cvshealth.com/

https://www.satellitehealth.com/

https://www.prnewswire.com/news-releases/cvs-kidney-care-satellite-healthcare-enter-strategic-relationship-to-advance-the-care-of-patients-with-kidney-disease-301014761.html

https://seekingalpha.com/symbol/CVS

Satellite Healthcare is one of the nation's leading not-for-profit providers of kidney dialysis and related services.

Thermo Fisher Scientific to Acquire QIAGEN N.V.

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

Thermo Fisher Scientific to Acquire QIAGEN N.V.

Tue March 3, 2020 2:53 AM|PR Newswire|About: QGEN, TMO

- Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies

- Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close

PR Newswire

WALTHAM, Mass. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and QIAGEN N.V. (QGEN)

https://www.thermofisher.com/us/en/home.html

https://www.qiagen.com/us/

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-qiagen-nv-301015072.html

https://seekingalpha.com/symbol/QGEN

https://seekingalpha.com/symbol/TMO

http://thermofisher.mediaroom.com/2020-03-03-Thermo-Fisher-Scientific-to-Acquire-QIAGEN-N-V,1

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

EC signs off on Allergan sale of brazikumab

Mar. 3, 2020 9:09 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/symbol/AZN

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html

AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan PUBLISHED 27 January 2020

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

Tue March 3, 2020 5:30 PM|Business Wire|About: BMY

NEW YORK & PARIS--(BUSINESS WIRE)-- Regulatory News:

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (BMY)

http://www.voluntis.com/

https://www.businesswire.com/news/home/20200303006062/en/

https://news.bms.com/press-release/httpwwwvoluntiscomennewsnews-12020voluntis-and-bristol-myers-squibb-co-develop-digital

https://seekingalpha.com/symbol/BMY

VOLUNTIS AND BRISTOL-MYERS SQUIBB TO CO-DEVELOP DIGITAL THERAPEUTICS FOR ONCOLOGY New York, NY and Paris, France, 03 March 2020 Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY)

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

Tue March 3, 2020 5:50 PM|Business Wire|About: ACAD

https://www.businesswire.com/news/home/20200303006075/en/

https://www.acadia-pharm.com/

https://www.acadia-pharm.com/pipeline/rett-syndrome/

https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-and-neuren-pharmaceuticals-announce-rare?field_nir_news_date_value[min]=

https://seekingalpha.com/symbol/ACAD

Trofinetide is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACADIA has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals.

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

Wed March 4, 2020 7:00 AM|Business Wire|About: ALNY, VIR

— Recent Alnylam (ALNY) advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses

— Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option for 50-50 participation

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc.

https://www.businesswire.com/news/home/20200304005363/en/

https://www.alnylam.com/

https://www.alnylam.com/alnylam-rnai-pipeline/

https://seekingalpha.com/symbol/ALNY

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) =Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19 03/04/20 at 7:05 AM EST

BiotechVortex™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Wed February 19, 2020 7:00 AM|Business Wire|About: DXCM, PODD

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control
Initially compatible with Dexcom G6 CGM, with no fingersticks* required
Integration with the next generation Dexcom G7 CGM system, once available

SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)-- DexCom (DXCM), Inc. (NASDAQ: DXCM) and Insulet Corporation (PODD)

http://www.insulet.com/

https://www.myomnipod.com/home

https://www.businesswire.com/news/home/20200219005028/en/

https://seekingalpha.com/symbol/DXCM

https://seekingalpha.com/symbol/PODD

Discover the Dexcom G6 CGM System

BMS-986249

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Bristol-Myers study expansions triggers $10M payment to CytomX

Feb. 24, 2020 8:16 AM ET|About: CytomX Therapeutics, Inc. (CTMX)|By: Liz Kiesche, SA News Editor

https://cytomx.com/

https://cytomx.com/pipeline/

https://seekingalpha.com/symbol/CTMX

Our expanding pipeline of ProbodyTM therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world’s leading biopharmaceutical companies.

Heartline™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Takeda Acquires PvP Biologics

Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke

Tue February 25, 2020 8:25 AM|PR Newswire|About: JNJ

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

PR Newswire

NEW BRUNSWICK, N.J., Feb. 25, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

https://www.heartline.com/

Johnson & Johnson Launches Heartline™, the First-of-Its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch can Help Reduce the Risk of Stroke

Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

Heart Health Education Play Video

New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ)

https://www.multivu.com/players/English/8693251-heartline-study/

https://www.jnj.com/

https://www.prnewswire.com/news-releases/johnson--johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke-301010792.html

Heartline™ =Johnson & Johnson, in collaboration with Apple, invites you to join the Heartline Study, a nationwide heart health research study for people 65+ with an iPhone. Receive heart health education and tips designed for people 65 and older Contribute to important medical research Eligible participants may earn compensation of $150+ for completing study activities*

Takeda Acquires PvP Biologics

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Takeda Acquires PvP Biologics

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

Wed February 26, 2020 2:00 AM|Business Wire|About: TAK

− Investigational medicine TAK-062 is an oral computationally engineered super glutenase designed to improve the digestion of gluten

− Successful “build to buy” relationship adds second investigational therapy to Takeda’s pipeline for the potential treatment of uncontrolled celiac disease

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

October 22, 2019

https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/

https://www.takeda.com/

https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes

https://www.businesswire.com/news/home/20200225005816/en/

https://www.pvpbio.com/

https://seekingalpha.com/symbol/TAK

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Wed February 26, 2020 8:30 AM|GlobeNewswire|About: AMGN, CYTK

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Topline Results Expected in Q4 2020

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier

https://www.amgen.com/

https://cytokinetics.com/

https://servier.com/en/

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Thu February 27, 2020 4:06 PM|Business Wire|About: BIIB, SGMO

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
Biogen’s access to Sangamo's gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases

CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) and Sangamo Therapeutics, Inc. (SGMO),

https://www.businesswire.com/news/home/20200227005961/en/

Sangamo and Biogen Neurology Collaboration

February 27, 2020

https://investor.sangamo.com/static-files/81a67847-1710-4716-9e98-4fb798cbef8a

https://www.biogen.com/

https://www.sangamo.com/

https://seekingalpha.com/symbol/BIIB

https://seekingalpha.com/symbol/SGMO

Sangamo and Biogen Neurology Collaboration February 27, 2020

BiotechVortex™

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Tue February 18, 2020 10:00 AM|GlobeNewswire|About: SNY

Sanofi (SNY) joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur,

https://www.sanofi.com/

https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00

https://seekingalpha.com/symbol/SNY

February 18 2020 Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

J & J to expand Partnership w/ Dept. of Health & Human Services to Accelerate COVID-19 Treatments

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments

Tue February 18, 2020 9:30 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., Feb. 18, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat

https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine

Novel Coronavirus, SARS-CoV-2

https://www.jnj.com/coronavirus

https://www.jnj.com/

https://www.janssen.com/

https://www.prnewswire.com/news-releases/johnson--johnson-to-expand-partnership-with-us-department-of-health--human-services-to-accelerate-the-discovery-of-potential-covid-19-treatments-301006642.html